Advaxis

Advaxis researches, develops and commercializes drugs, vaccines and immunotherapies for the treatment of cancer. Read more

471 Followers on Owler
471 Followers on Owler
471 Followers on Owler
471 Followers on Owler

Advaxis

Advaxis researches, develops and commercializes drugs, vaccines and immunotherapies for the treatment of cancer. Read more

Kenneth A. Berlin's photo - President & CEO of Advaxis

President & CEO

Kenneth A. Berlin

CEO Approval Rating

66/100

Founded:

2002

Status:

PublicIndependent CompanyNASDAQADXS

ADVAXIS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

NexImmune is the top competitor of Advaxis. NexImmune was founded in 2011, and its headquarters is in Gaithersburg, Maryland. Like Advaxis, NexImmune also operates in the Biotechnology field. NexImmune has 9 more employees than Advaxis.

Immune Design is seen as one of Advaxis's top competitors. Immune Design was founded in Seattle, Washington} in 2008. Like Advaxis, Immune Design also works within the Biotechnology field. Compared to Advaxis, Immune Design generates $331K more revenue.

Selecta Biosciences is Advaxis's #3 rival. Selecta Biosciences's headquarters is in Watertown, Massachusetts, and was founded in 2007. Like Advaxis, Selecta Biosciences also operates in the Biotechnology sector. Selecta Biosciences generates 889% of Advaxis's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Aura Biosciences a competitor of Advaxis?

Advaxis Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$1.9M

Advaxis's revenue is the ranked 12th among it's top 10 competitors. The top 10 competitors average 3.1B. Over the last two quarters, Advaxis's revenue has grown by 546%. Specifically, in Q1 2021's revenue was $1.6M; in Q2 2020, it was $ < 1M.

Advaxis Acquisitions

No recent acquisitions found related to Advaxis

Advaxis Funding History

Since Advaxis was founded in 2002, it has participated in 12 rounds of funding. In total Advaxis has raised $83.6M. Advaxis' last funding round was on Aug 2016 for a total of $30.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Aug 2016
$30M
-
Equity
Aug 2015
$25M
Debt
May 2012
$715K
-
Equity
May 2012
$4.5M
-
Debt
Jan 2012
$1M
-

Since Advaxis was founded in 2002, it has participated in 12 rounds of funding. In total Advaxis has raised $83.6M. Advaxis' last funding round was on Aug 2016 for a total of $30.0M

Advaxis Investments

No recent investments found related to Advaxis

Advaxis News

April 10, 2021Markets Insider

Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting

Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a ... See more »
March 23, 2021Markets Insider

Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference

PRINCETON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage bi... See more »
March 16, 2021BioSpace

Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and c... See more »
January 25, 2021BioSpace

Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update

Advaxis today announces its financial results for the fiscal year ended October 31, 2020 and provides... See more »
December 16, 2020Micro Small Cap

Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Advaxis, Inc.- ADXS

New York, New York-(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced... See more »
November 29, 2020Philadelphia Citybizlist

Advaxis Closes $9.2M Public Offering

November 27, 2020BioSpace

Advaxis, Inc. Announces Closing of $9.2 Million Public Offering

PRINCETON, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the "Company"), a cl... See more »

Advaxis Blogs

August 24, 2015ADVAXIS BLOG

Peter Bloch

The post Peter Bloch appeared first on The Chairman's Blog.... See more »
July 23, 2015ADVAXIS BLOG

Sergio Traversa, PharmD, MBA

July 22, 2015ADVAXIS BLOG

Paula T. Trzepacz, M.D.

July 17, 2015ADVAXIS BLOG

François Desjardins

July 10, 2015ADVAXIS BLOG

Dr. Nicole Gibran

July 9, 2015ADVAXIS BLOG

Scott Maguire, MBA

July 8, 2015ADVAXIS BLOG

James W. Dowe III

Advaxis Press Releases

January 19, 2021GlobeNewswire

Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

Non-dilutive capital strengthens balance sheet to further advance ADXS-HOT neoantigen programNon-dilu... See more »
December 22, 2020GlobeNewswire

Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

PRINCETON, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage bio... See more »
November 9, 2020GlobalNewswire

Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with imm... See more »
October 26, 2020GlobalNewswire

Advaxis' ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial

Disease control rate of 67% in first six evaluable patients who had progressed on KEYTRUDA... See more »
September 29, 2020GlobeNewswire

Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan

PRINCETON, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage bi... See more »
September 24, 2020GlobeNewswire

Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer

Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND... See more »
August 27, 2020GlobeNewswire

Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference

PRINCETON, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage bio... See more »

Advaxis Videos

Social Media

Advaxis Headquarters

305 College Road East

Princeton, New Jersey08540

1-609-452-9813

Driving Directions »

Trending Companies

Advaxis Summary

ABOUT

Overview

Advaxis researches, develops and commercializes drugs, vaccines and immunotherapies for the treatment of cancer. Advaxis was founded in 2002. Advaxis' headquarters is located in Princeton, New Jersey, USA 08540. It has raised 83.6M in 12 rounds. The l...

CEO

Advaxis's President & CEO, Kenneth A. Berlin, currently has an approval rating of 66%. Advaxis's primary competitors are NexImmune, Immune Design & Selecta Biosciences.

Website

advaxis.com

Frequently Asked Questions about Advaxis

  1. When was Advaxis founded?

    Advaxis was founded in 2002
  2. Who is Advaxis's CEO?

    Advaxis's CEO is Kenneth A. Berlin
  3. How much revenue does Advaxis generate?

    Advaxis generates $1.9M in revenue
  4. How much funding does Advaxis have?

    Advaxis has historically raised $83.6M in funding
  1. Where is Advaxis's headquarters?

    Advaxis's headquarters is in Princeton New Jersey, USA
  2. How many employees does Advaxis have?

    Advaxis has 35 employees
  3. What sector does Advaxis operate in?

    Advaxis is in Biotechnology
  4. Who are Advaxis's competitors?

    Advaxis's top competitors are NexImmune, Immune Design, Selecta Biosciences